Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Simonella, Leonardo M ^a,b   Lewis, Hazel ^c   Smith, Megan ^a,d   Neal, Harold ^c   Bromhead, Collette ^e   Canfell, Karen ^a,d,f  

^a CANCER RESEARCH DIVISION   (Australia)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c MINISTRY OF HEALTH   (New Zealand)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Molecular Biology Department   (New Zealand)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADENOCARCINOMA; ADENOCARCINOMA IN SITU; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CYTOLOGY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 26; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 40; HUMAN PAPILLOMAVIRUS TYPE 42; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 54; HUMAN PAPILLOMAVIRUS TYPE 55; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 61; HUMAN PAPILLOMAVIRUS TYPE 62; HUMAN PAPILLOMAVIRUS TYPE 64; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 67; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 69; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN PAPILLOMAVIRUS TYPE 71; HUMAN PAPILLOMAVIRUS TYPE 72; HUMAN PAPILLOMAVIRUS TYPE 73; HUMAN PAPILLOMAVIRUS TYPE 81; HUMAN PAPILLOMAVIRUS TYPE 82; HUMAN PAPILLOMAVIRUS TYPE 83; HUMAN PAPILLOMAVIRUS TYPE 84; HUMAN PAPILLOMAVIRUS TYPE CP6108; HUMAN PAPILLOMAVIRUS TYPE IS39; HUMAN TISSUE; INFECTION RATE; MAJOR CLINICAL STUDY; MASS SCREENING; NEW ZEALAND; ONCOGENE; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PREVALENCE; SPECIES DIFFERENTIATION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DISEASE; VACCINATION; VIRUS IDENTIFICATION; WART VIRUS;

ADENOCARCINOMA; ADULT; AGED; AUSTRALIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; NEW ZEALAND; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL NEOPLASMS;

EID: 84874397011     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-114     Document Type: Article

References (30)

1. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97(14):1072-1079. 10.1093/jnci/dji187, 16030305.
2. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 337(1):76-84. 10.1016/j.virol.2005.04.002, 15914222.
3. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, Clifford GM. Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int J Cancer 2012, 131(10):2349-59. 10.1002/ijc.27485, 22323075.
4. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003, 89(1):101-105. 10.1038/sj.bjc.6601024, 2394204, 12838308.
5. Castellsagué X, de Sanjosé S, Aguado T, Louie KS, Bruni L, Muñoz J, Diaz M, Irwin K, Gacic M, Beauvais O. HPV and Cervical Cancer in the World: 2007 Report. Vaccine 2007, 25(Supplement 3):C22.
6. Australian Bureau of Statistics Topics at a glance - Aboriginal and Torres Strait Islander Peoples Population 2007, Canberra: Australian Bureau of Statistics, http://www.abs.gov.au/websitedbs/c311215.nsf/web/Aboriginal+and+Torres+Strait+Islander+Peoples+-+Population ISBN Topics at a glance - Aboriginal and Torres Strait Islander Peoples Population, Australian Bureau of Statistics.
7. Statistics New Zealand 2006 Census 2007, Wellington: Statistics New Zealand, http://www.stats.govt.nz/Census/2006CensusHomePage.aspx, Statistics New Zealand.
8. Brotherton JM. How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine 2008, 26(2):250-256. 10.1016/j.vaccine.2007.10.057, 18068276.
9. Stevens MP, Garland SM, Tan JH, Quinn MA, Petersen RW, Tabrizi SN. HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. J Med Virol 2009, 81(7):1283-1291. 10.1002/jmv.21515, 19475612.
10. Brestovac B, Harnett GB, Smith DW, Shellam GR, Frost FA. Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women. J Med Virol 2005, 76(1):106-110. 10.1002/jmv.20330, 15778980.
11. Garland SM, Brotherton JM, Condon JR, McIntyre PB, Stevens MP, Smith DW, Tabrizi SN, . group tWs Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med 2011, 9(1):104. 10.1186/1741-7015-9-104, 3182900, 21910918, group tWs.
12. HPV Project Team The HPV (Human papillomavirus) Immunisation Programme. National Implementation Strategic overview 2008, New Zealand: Ministry of Health: Public Health Department, Ministry of Health, HPV Project Team.
13. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, . Future I-II Study Group Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 341:c3493. 2907480, 20647284, Future I-II Study Group.
14. Future II group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927. Future II group.
15. Smith M, Walker R, Clements M, Canfell K. National Cervical Screening Programme Monitoring Report Number 32, 1 July - 31 December 2009. National Cervical Screening Programme Monitoring Reports 2010, New Zealand: Ministry of Health National Screening Unit, Register NCSP.
16. New Zealand National Cervical Screening Programme Bethesda 2001 New Zealand Modified: Codes, descriptors and assessment of sample adequacy for cytology laboratories 2005, New Zealand: New Zealand National Cervical Screening Programme, New Zealand National Cervical Screening Programme.
17. Howell-Jones R, Bailey A, Beddows S, Sargent A, de Silva N, Wilson G, Anton J, Nichols T, Soldan K, Kitchener H. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 2010, 103(2):209-216. 10.1038/sj.bjc.6605747, 2906740, 20628396.
18. Stevens MP, Rudland E, Garland SM, Tabrizi SN. Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J Clin Microbiol 2006, 44(7):2428-2433. 10.1128/JCM.02608-05, 1489532, 16825360.
19. Stevens MP, Tabrizi SN, Quinn MA, Garland SM. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer 2006, 16(3):1017-1024. 10.1111/j.1525-1438.2006.00453.x, 16803479.
20. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38(1):357-361. 88724, 10618116.
21. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009, 10(4):321-322. 10.1016/S1470-2045(09)70096-8, 19350698.
22. Smith M, Walker R, Clemens M, Canfell K, Lewis L, Neal H, Maxwell A. National Cervical Screening Programme Monitoring Report Number 32 1 July - 31 December 2009 2011, New Zealand: New Zealand National Cervical Screening Programme.
23. Stevens MP, Garland SM, Tabrizi SN. Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods 2008, 147(2):290-296. 10.1016/j.jviromet.2007.09.018, 17996311.
24. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632. 10.1002/ijc.22527, 17405118.
25. Porras C, Rodríguez AC, Hildesheim A, Herrero R, González P, Wacholder S, Burk RD, Schiffman M. Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. Cancer Epidemiol Biomarkers Prev 2009, 18(3):863-865. 10.1158/1055-9965.EPI-08-0951, 2772192, 19273486.
26. Miyamoto J, Berkowitz Z, Unger E, Lyu C, Copeland G, Lynch C, Sibug-Saber M, Saraiya M. Vaccine-type HPV distribution in CIN3/AIS: 3 U.S. cancer registries, 1994-2005. 27th Internation Papillomavirus conference and clinical workshop 2011, 40. Berlin, Germany, Volume Abstract Book 1.
27. Baandrup L, Munk C, Andersen KK, Junge J, Iftner T, Kjær SK. HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. Gynecol Oncol 2012, 124(2):281-285. 10.1016/j.ygyno.2011.10.020, 22036987.
28. Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, Hildesheim A, Herrero R, Bratti MC, Sherman ME. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002, 68(3):417-423. 10.1002/jmv.10220, 12226831.
29. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003, 31:14-19.
30. Brotherton JML, Kaldor JM, Garland SM. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Sexual Health 2010, 7(3):310-319. 10.1071/SH09137, 20719220.